SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-017660
Filing Date
2023-11-06
Accepted
2023-11-06 07:30:34
Documents
70
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20230930x10q.htm   iXBRL 10-Q 1923189
2 EX-31.1 acrs-20230930xex31d1.htm EX-31.1 15626
3 EX-31.2 acrs-20230930xex31d2.htm EX-31.2 15666
4 EX-32.1 acrs-20230930xex32d1.htm EX-32.1 9521
  Complete submission text file 0001558370-23-017660.txt   8102859

Data Files

Seq Description Document Type Size
5 EX-101.SCH acrs-20230930.xsd EX-101.SCH 41008
6 EX-101.CAL acrs-20230930_cal.xml EX-101.CAL 46622
7 EX-101.DEF acrs-20230930_def.xml EX-101.DEF 194839
8 EX-101.LAB acrs-20230930_lab.xml EX-101.LAB 441455
9 EX-101.PRE acrs-20230930_pre.xml EX-101.PRE 309702
64 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230930x10q_htm.xml XML 1657606
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 231378116
SIC: 2834 Pharmaceutical Preparations